Eli Lilly and Company announced Thursday plans to conclude production and pursue a sale of one of its Guayama plant, one of three operations it has in Puerto Rico. The site will remain in production until the end of 2015, company officials said.
In response to the growing diabetes epidemic and increasing demand for insulin around the world, pharmaceutical company Eli Lilly and Co. announced Thursday it will invest more than $700 million to enhance its insulin manufacturing capacity in Puerto Rico, France and China, as well as in its Indianapolis global headquarters.
Shooting down reports circulated Tuesday saying it planned to close its Guayama operation, pharmaceutical company Lilly del Caribe announced and launched a voluntary severance program for eligible employees working at the site.
A Dow Jones/Factiva content provider since 2014
Subscribe to our Dollars & Sense podcast!
